TETSUO ASHIZAWA to Clinical Trials as Topic
This is a "connection" page, showing publications TETSUO ASHIZAWA has written about Clinical Trials as Topic.
Connection Strength
0.099
-
Towards development of a statistical framework to evaluate myotonic dystrophy type 1 mRNA biomarkers in the context of a clinical trial. PLoS One. 2020; 15(4):e0231000.
Score: 0.029
-
Rare neurological channelopathies--networks to study patients, pathogenesis and treatment. Nat Rev Neurol. 2016 Apr; 12(4):195-203.
Score: 0.022
-
Emerging therapies in Friedreich's ataxia. Neurodegener Dis Manag. 2016; 6(1):49-65.
Score: 0.022
-
Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord. 2010 Mar 15; 25(4):426-32.
Score: 0.014
-
Antioxidant use in Friedreich ataxia. J Neurol Sci. 2008 Apr 15; 267(1-2):174-6.
Score: 0.012